Hjem
Universitetet i Bergen
Rebecca Jane Cox Brokstads bilde

Rebecca Jane Cox Brokstad

Professor, Leder av Influensasenteret
Klinisk institutt 2
Influensasenteret
  • E-postRebecca.Cox@uib.no
  • Telefon+47 55 97 46 68+47 452 42 974
  • Besøksadresse
    Laboratoriebygget 5. etg
    Jonas Lies vei 87
    5021 Bergen
    Rom 
    Kontor 114 Armauer Hansens hus
  • Postadresse
    Postboks 7804
    5020 Bergen
Vitenskapelig artikkel
  • Vis forfatter(e) (2024). Symptom trajectories of post-COVID sequelae in patients with acute Delta or Omicron infection in Bergen, Norway. Frontiers in Public Health.
  • Vis forfatter(e) (2024). Impact of ageing on homologous and human-coronavirus-reactive antibodies after SARS-CoV-2 vaccination or infection. npj Vaccines. 9 sider.
  • Vis forfatter(e) (2023). Vaccination prevents severe COVID-19 outcome in patients with neutralizing type 1 interferon autoantibodies. iScience. 18 sider.
  • Vis forfatter(e) (2023). VACCELERATE Site Network: Real-time definition of clinical study capacity in Europe. Vaccine. 3915-3922.
  • Vis forfatter(e) (2023). The Challenges of Vaccine Trial Participation among Underserved and Hard-to-Reach Communities: An Internal Expert Consultation of the VACCELERATE Consortium. Vaccines.
  • Vis forfatter(e) (2023). SARS-CoV-2 specific immune responses in overweight and obese COVID-19 patients. Frontiers in Immunology. 11 sider.
  • Vis forfatter(e) (2023). Risk assessment and antibody responses to SARS-CoV-2 in healthcare workers. Frontiers in Public Health. 13 sider.
  • Vis forfatter(e) (2023). Prolonging the delivery of influenza virus vaccine improves the quantity and quality of the induced immune responses in mice. Frontiers in Immunology.
  • Vis forfatter(e) (2023). Proficiency tests to evaluate the impact on assay outcomes of harmonized influenza-specific Intracellular Cytokine Staining (ICS) and IFN-ɣ Enzyme-Linked ImmunoSpot (ELISpot) protocols. Journal of Immunological Methods (JIM).
  • Vis forfatter(e) (2023). Post COVID-19 condition after delta infection and omicron reinfection in children and adolescents. EBioMedicine. 10 sider.
  • Vis forfatter(e) (2023). Human anti-N1 monoclonal antibodies elicited by pandemic H1N1 virus infection broadly inhibit HxN1 viruses in vitro and in vivo. Immunity. 1927-1938.e8.
  • Vis forfatter(e) (2023). Haemagglutination inhibition and virus microneutralisation serology assays: use of harmonised protocols and biological standards in seasonal influenza serology testing and their impact on inter-laboratory variation and assay correlation: A FLUCOP collaborative study. Frontiers in Immunology. 16 sider.
  • Vis forfatter(e) (2023). Enhancing Public Health Communication Regarding Vaccine Trials: Design and Development of the Pan-European VACCELERATE Toolkit. JMIR Public Health and Surveillance. 8 sider.
  • Vis forfatter(e) (2023). Durable immune responses after BNT162b2 vaccination in home-dwelling old adults. Vaccine: X. 1-11.
  • Vis forfatter(e) (2023). Distinct receptor binding domain IgG thresholds predict protective host immunity across SARS-CoV-2 variants and time. Nature Communications. 11 sider.
  • Vis forfatter(e) (2023). An external quality assessment feasibility study; cross laboratory comparison of haemagglutination inhibition assay and microneutralization assay performance for seasonal influenza serology testing: A FLUCOP study. Frontiers in Immunology. 15 sider.
  • Vis forfatter(e) (2022). Validation of a Harmonized Enzyme-Linked-Lectin-Assay (ELLA-NI) Based Neuraminidase Inhibition Assay Standard Operating Procedure (SOP) for Quantification of N1 Influenza Antibodies and the Use of a Calibrator to Improve the Reproducibility of the ELLA-NI With Reverse Genetics Viral and Recombinant Neuraminidase Antigens: A FLUCOP Collaborative Study. Frontiers in Immunology. 17 sider.
  • Vis forfatter(e) (2022). Vaccination rates in Europe are not associated with online media intensity. JCOM - Journal of Science Communication. 15 sider.
  • Vis forfatter(e) (2022). VACCELERATE Volunteer Registry: A European study participant database to facilitate clinical trial enrolment. Vaccine. 4090-4097.
  • Vis forfatter(e) (2022). Titers of antibodies against ancestral SARS-CoV-2 correlate with levels of neutralizing antibodies to multiple variants. npj Vaccines. 11 sider.
  • Vis forfatter(e) (2022). The performances of three commercially available assays for the detection of SARS‐CoV‐2 antibodies at different time points following SARS‐CoV‐2 infection. Viruses. 1-11.
  • Vis forfatter(e) (2022). The evolution of humoral immune responses to past and novel influenza virus strains gives evidence for antigenic seniority. Frontiers in Immunology. 1-15.
  • Vis forfatter(e) (2022). Symptom Burden and Immune Dynamics 6 to 18 Months Following Mild Severe Acute Respiratory Syndrome Coronavirus 2 Infection (SARS-CoV-2): A Case-control Study. Clinical Infectious Diseases.
  • Vis forfatter(e) (2022). Seasonal influenza vaccination expands hemagglutinin-specific antibody breadth to older and future A/H3N2 viruses. npj Vaccines. 10 sider.
  • Vis forfatter(e) (2022). SARS CoV-2 Infection among Health Care Workers from Different Health Care Facilities in Western Norway: A Prospective, Cross-Sectional Study. Viruses. 8 sider.
  • Vis forfatter(e) (2022). Human organotypic airway and lung organoid cells of bronchiolar and alveolar differentiation are permissive to infection by influenza and SARS-CoV-2 respiratory virus. Frontiers in Cellular and Infection Microbiology. 1-23.
  • Vis forfatter(e) (2022). Harmonization and qualification of intracellular cytokine staining to measure influenza-specific CD4<sup>+</sup> T cell immunity within the FLUCOP consortium. Frontiers in Immunology. 14 sider.
  • Vis forfatter(e) (2022). Harmonization and qualification of an IFN-γ Enzyme-Linked ImmunoSpot assay (ELISPOT) to measure influenza-specific cell-mediated immunity within the FLUCOP consortium. Frontiers in Immunology. 14 sider.
  • Vis forfatter(e) (2022). Factors that impact on recruitment to vaccine trials during a pandemic or epidemic: a qualitative evidence synthesis. Cochrane Database of Systematic Reviews. 13 sider.
  • Vis forfatter(e) (2022). Durable T-cellular and humoral responses in SARS-CoV-2 hospitalized and community patients. PLOS ONE. 16 sider.
  • Vis forfatter(e) (2022). A rapid antibody screening haemagglutination test for predicting immunity to SARS-CoV-2 variants of concern. Communications Medicine. 11 sider.
  • Vis forfatter(e) (2022). A Novel Prophylaxis Strategy Using Liposomal Vaccine Adjuvant CAF09b Protects against Influenza Virus Disease. International Journal of Molecular Sciences.
  • Vis forfatter(e) (2021). Safety, Immunogenicity, Efficacy and Effectiveness of Inactivated Influenza Vaccines in Healthy Pregnant Women and Children Under 5 Years: An Evidence-Based Clinical Review. Frontiers in Immunology. 16 sider.
  • Vis forfatter(e) (2021). Repeated Influenza Vaccination Boosts and Maintains H1N1pdm09 Neuraminidase Antibody Titers. Frontiers in Immunology. 1-11.
  • Vis forfatter(e) (2021). Persistently high antibody responses after AS03-adjuvanted H1N1pdm09 vaccine: Dissecting the HA specific antibody response. npj Vaccines. 1-6.
  • Vis forfatter(e) (2021). Matrix M Adjuvanted H5N1 Vaccine Elicits Broadly Neutralizing Antibodies and Neuraminidase Inhibiting Antibodies in Humans That Correlate With In Vivo Protection. Frontiers in Immunology. 1-13.
  • Vis forfatter(e) (2021). Lower antibiotic prescription rates in hospitalized COVID-19 patients than influenza patients, a prospective study. Infectious Diseases. 1-12.
  • Vis forfatter(e) (2021). Long COVID in a prospective cohort of home-isolated patients. Nature Medicine. 1607-1613.
  • Vis forfatter(e) (2021). Learning from the COVID-19 pandemic among migrants: An innovative, system-level, interdisciplinary approach is needed to improve public health . Scandinavian Journal of Public Health. 804-808.
  • Vis forfatter(e) (2021). Humoral and cellular immune responses in critically ill influenza A/H1N1-infected patients. Scandinavian Journal of Immunology. 1-9.
  • Vis forfatter(e) (2021). Functional and Binding H1N1pdm09-Specific Antibody Responses in Occasionally and Repeatedly Vaccinated Healthcare Workers: A Five-Year Study (2009-2014). Frontiers in Immunology.
  • Vis forfatter(e) (2021). Attack rates amongst household members of outpatients with confirmed COVID-19 in Bergen, Norway: A case-ascertained study. The Lancet Regional Health - Europe. 9 sider.
  • Vis forfatter(e) (2021). Assay harmonization and use of biological standards to improve the reproducibility of the hemagglutination inhibition assay: A FLUCOP collaborative study. mSphere. 1-18.
  • Vis forfatter(e) (2020). Viral antigens elicit augmented immune responses in primary Sjögren's syndrome. Rheumatology. 1651-1661.
  • Vis forfatter(e) (2020). Third human challenge trial conference, Oxford, United Kingdom, February 6–7, 2020, a meeting report. Biologicals (Print). 41-52.
  • Vis forfatter(e) (2020). SARS-CoV-2-specific neutralizing antibody responses in Norwegian healthcare workers after the first wave of COVID-19 pandemic: a prospective cohort study. Journal of Infectious Diseases.
  • Vis forfatter(e) (2020). Responsiveness to influenza vaccination correlates with nkg2c-expression on nk cells. Vaccines. 1-18.
  • Vis forfatter(e) (2020). Point-of-care influenza testing impacts clinical decision, patient flow and length of stay in hospitalized adults. Journal of Infectious Diseases. 97-108.
  • Vis forfatter(e) (2020). Live-attenuated influenza vaccine induces tonsillar follicular T helper cell responses that correlate with antibody induction. Journal of Infectious Diseases. 21-32.
  • Vis forfatter(e) (2020). Human antibodies targeting influenza B virus neuraminidase active site are broadly protective. Immunity. 852-863.
  • Vis forfatter(e) (2020). Early Induction of Cross-Reactive CD8+ T-Cell Responses in Tonsils After Live-Attenuated Influenza Vaccination in Children. Journal of Infectious Diseases. 1528-1537.
  • Vis forfatter(e) (2019). Vitamin D Deficiency is Associated with Increased Use of Antimicrobials among Preschool Girls in Ethiopia. Nutrients. 1-14.
  • Vis forfatter(e) (2019). No evidence of antigenic seniority in hemagglutinin specific antibody responses after adjuvanted pandemic 2009 influenza vaccination. Vaccine: X. 1-8.
  • Vis forfatter(e) (2019). Meeting report and review: Immunological assays and correlates of protection for next-generation influenza vaccines. Influenza and Other Respiratory Viruses. 1-7.
  • Vis forfatter(e) (2019). Low temperature and low UV indexes correlated with peaks of influenza virus activity in Northern Europe during 2010-2018. Viruses. 1-10.
  • Vis forfatter(e) (2019). Functional immune response to influenza H1N1 in children and adults after live attenuated influenza virus vaccination. Scandinavian Journal of Immunology. 1-12.
  • Vis forfatter(e) (2019). Common nodes of virus-host interaction revealed through an integrated network analysis. Frontiers in Immunology. 12 sider.
  • Vis forfatter(e) (2018). T follicular-like helper cells in the peripheral blood of patients with primary Sjögren's syndrome. Scandinavian Journal of Immunology. 1-15.
  • Vis forfatter(e) (2018). Novel activities of safe-in-human broad-spectrum antiviral agents. Antiviral Research. 174-182.
  • Vis forfatter(e) (2018). Impact of pre-existing immunity on the induction of functional cross-reactive anti-hemagglutinin stalk antibodies following vaccination with an AS03 adjuvanted pandemic H1N1 vaccine. Vaccine. 2213-2219.
  • Vis forfatter(e) (2018). Impact of erythrocyte species on assays for influenza serology. Journal of Preventive Medicine and Hygiene (JPMH). E1-E7.
  • Vis forfatter(e) (2018). Augmented CD4+ T-cell and humoral responses after repeated annual influenza vaccination with the same vaccine component A/H1N1pdm09 over 5 years. npj Vaccines. 10 sider.
  • Vis forfatter(e) (2018). Antibody responses to influenza A/H1N1pdm09 virus after pandemic and seasonal influenza vaccination in healthcare workers: A 5-year follow-up study. Clinical Infectious Diseases. 382-392.
  • Vis forfatter(e) (2018). Antibody response to seasonal influenza vaccination in patients with multiple sclerosis receiving immunomodulatory therapy. European Journal of Neurology. 527-534.
  • Vis forfatter(e) (2018). Antibody levels in a cohort of pregnant women after the 2009 influenza A(H1N1) pandemic: Waning and association with self-reported severity and duration of illness. Influenza and Other Respiratory Viruses. 191-200.
  • Vis forfatter(e) (2017). Mucosal administration of cycle-di-nucleotide-adjuvanted virosomes efficiently induces protection against influenza H5N1 in mice. Frontiers in Immunology. 1-15.
  • Vis forfatter(e) (2017). Influenza virus hemagglutinin stalk-specific antibodies in human serum are a surrogate marker for in vivo protection in a serum transfer mouse challenge model. mBio. 1-13.
  • Vis forfatter(e) (2017). Influenza A haemagglutinin specific IgG responses in children and adults after seasonal trivalent live attenuated influenza vaccination. Vaccine. 5666-5673.
  • Vis forfatter(e) (2017). High prevalence of humoral and cellular immunity to influenza viruses in preschool children living in Addis Ababa, Ethiopia. Open Forum Infectious Diseases. 6 sider.
  • Vis forfatter(e) (2017). Distinct T and NK cell populations may serve as immune correlates of protection against symptomatic pandemic influenza A(H1N1) virus infection during pregnancy. PLOS ONE. 14 sider.
  • Vis forfatter(e) (2017). Boosting of cross-reactive and protection-associated T cells in children after live attenuated influenza vaccination. Journal of Infectious Diseases. 1527-1535.
  • Vis forfatter(e) (2017). A DNA vaccine that targets hemagglutinin to antigen-presenting cells protects mice against H7 influenza. Journal of Virology. 1-13.
  • Vis forfatter(e) (2016). Self-reported influenza vaccination and protective serum antibody titers in a cohort of COPD patients. Respiratory Medicine. 53-59.
  • Vis forfatter(e) (2016). Salivary IgA from the sublingual compartment as a novel noninvasive proxy for intestinal immune induction. Mucosal Immunology. 884-893.
  • Vis forfatter(e) (2016). Pulmonary changes in Norwegian fatal cases of pandemic influenza H1N1 (2009) infection: a morphologic and molecular genetic study. Influenza and Other Respiratory Viruses. 525-531.
  • Vis forfatter(e) (2016). Long-term maintenance of the influenza-specific cross-reactive memory CD4+ T-cell responses following repeated annual influenza vaccination. Journal of Infectious Diseases. 740-749.
  • Vis forfatter(e) (2016). Live attenuated influenza vaccine in children induces b-cell responses in tonsils. Journal of Infectious Diseases. 722-731.
  • Vis forfatter(e) (2016). Interpandemic (Seasonal) influenza. ERS Monograph. 35-64.
  • Vis forfatter(e) (2016). Humoral, T-cell and B-cell immune responses to seasonal influenza vaccine in solid organ transplant recipients receiving anti-T cell therapies. Vaccine. 3576-3583.
  • Vis forfatter(e) (2016). Epitope specific T-cell responses against influenza A in a healthy population. Immunology. 165-177.
  • Vis forfatter(e) (2016). Dissecting the hemagglutinin head and stalk-specific IgG antibody response in healthcare workers following pandemic H1N1 vaccination. npj Vaccines.
  • Vis forfatter(e) (2016). Comparative analysis of influenza A(H3N2) virus hemagglutinin specific IgG subclass and IgA responses in children and adults after influenza vaccination. Vaccine. 191-198.
  • Vis forfatter(e) (2015). Validation of Single Radial Haemolysis assay: A reliable method to measure antibodies against influenza viruses. Journal of Immunological Methods (JIM). 95-101.
  • Vis forfatter(e) (2015). Vaccination with adjuvanted recombinant neuraminidase induces broad heterologous, but not heterosubtypic, cross-protection against influenza virus infection in mice. mBio. 13 sider.
  • Vis forfatter(e) (2015). The expression of B & T cell activation markers in children’s tonsils following live attenuated influenza vaccine. Human Vaccines & Immunotherapeutics. 1663-1672.
  • Vis forfatter(e) (2015). The effectiveness of convalescent plasma and hyperimmune immunoglobulin for the treatment of severe acute respiratory infections of viral etiology: A systematic review and exploratory meta-analysis. Journal of Infectious Diseases. 80-90.
  • Vis forfatter(e) (2015). Single dose vaccination of the ASO3-adjuvanted A (H1N1)pdm09 monovalent vaccine in health care workers elicits homologous and cross-reactive cellular and humoral responses to H1N1 strains. Human Vaccines & Immunotherapeutics. 1654-1662.
  • Vis forfatter(e) (2015). Persistence and avidity maturation of antibodies to A(H1N1)pdm09 in healthcare workers following repeated annual vaccinations. Vaccine. 4146-4154.
  • Vis forfatter(e) (2015). Need for more targeted measures - Only less severe hospital-associated infections declined after introduction of an infection control program. Journal of Infection and Public Health. 282-290.
  • Vis forfatter(e) (2015). Mortality related to hospital-associated infections in a tertiary hospital; repeated cross-sectional studies between 2004-2011. Antimicrobial Resistance and Infection Control. 1-8.
  • Vis forfatter(e) (2015). Matrix M H5N1 vaccine induces cross-H5 clade humoral immune responses in a randomized clinical trial and provides protection from highly pathogenic influenza challenge in ferrets. PLOS ONE.
  • Vis forfatter(e) (2015). Longevity of B-cell and T-cell responses after live attenuated influenza vaccination in children. Journal of Infectious Diseases. 1541-1549.
  • Vis forfatter(e) (2015). Intranasal vaccination with a plant-derived H5 HA vaccine protects mice and ferrets against highly pathogenic avian influenza virus challenge. Human Vaccines & Immunotherapeutics. 1235-1243.
  • Vis forfatter(e) (2015). Influenza Vaccination Strategies: Comparing Inactivated and Live Attenuated Influenza Vaccines. Vaccines. 373-389.
  • Vis forfatter(e) (2015). Induction of local secretory IgA and multifunctional CD4+ T-helper cells following intranasal immunization with a H5N1 whole inactivated influenza virus vaccine in BALB/c mice. Scandinavian Journal of Immunology. 305-317.
  • Vis forfatter(e) (2015). Immune responses in acute and convalescent patients with mild, moderate and severe disease during the 2009 influenza pandemic in Norway. PLOS ONE. 16 sider.
  • Vis forfatter(e) (2014). The Influence of Tonsillectomy on Total Serum Antibody Levels. Scandinavian Journal of Immunology. 377-379.
  • Vis forfatter(e) (2014). Serum IgG titres, but not avidity, correlates with neutralizing antibody response after H5N1 vaccination. Vaccine. 4550-4557.
  • Vis forfatter(e) (2014). Matrix M™ adjuvanted virosomal H5N1 vaccine induces balanced Th1/Th2 CD4+ T cell responses in man. Human Vaccines & Immunotherapeutics. 2408-2416.
  • Vis forfatter(e) (2014). Intranasal H5N1 vaccines, adjuvanted with chitosan derivatives, protect ferrets against highly pathogenic influenza intranasal and intratracheal challenge. PLOS ONE.
  • Vis forfatter(e) (2014). Induction of broadly reactive anti-hemagglutinin stalk antibodies by an H5N1 vaccine in humans. Journal of Virology. 13260-13268.
  • Vis forfatter(e) (2014). Immunotherapies influence the influenza vaccination response in multiple sclerosis patients: An explorative study. Multiple Sclerosis. 1074-1080.
  • Vis forfatter(e) (2014). Experimental infection of healthy volunteers with enterotoxigenic Escherichia coli wild-type strain TW10598 in a hospital ward. BMC Infectious Diseases. 9 sider.
  • Vis forfatter(e) (2014). Divergent H7 immunogens offer protection from H7N9 virus challenge. Journal of Virology. 3976-3985.
  • Vis forfatter(e) (2014). An H7N1 influenza virus vaccine induces broadly reactive antibody responses against H7N9 in humans. Clinical and Vaccine Immunology. 1153-1163.
  • Vis forfatter(e) (2013). A study of Chitosan and c-di-GMP as mucosal adjuvants for intranasal influenza H5N1 vaccine. Influenza and Other Respiratory Viruses. 1181-1193.
  • Vis forfatter(e) (2012). The mucosal and systemic immune responses elicited by a chitosan-adjuvanted intranasal influenza H5N1 vaccine. Influenza and Other Respiratory Viruses. 90-100.
  • Vis forfatter(e) (2012). The human potential of a recombinant pandemic influenza vaccine produced in tobacco plants. Human Vaccines & Immunotherapeutics. 653-661.
  • Vis forfatter(e) (2012). T-helper 1 cells elicited by H5N1 vaccination predict seroprotection. Journal of Infectious Diseases. 158-166.
  • Vis forfatter(e) (2012). Influenza-like illness in general practice in Norway: clinical course and attitudes towards vaccination and preventive measures during the 2009 pandemic. Family Practice. 139-146.
  • Vis forfatter(e) (2012). A(H1N1)pdm09 Vaccination of Health Care Workers: Improved Immune Responses in Low Responders Following Revaccination. Journal of Infectious Diseases. 1660-1669.
  • Vis forfatter(e) (2011). Pandemic influenza vaccination of hypogammaglobulinemic patients induces normal or elevated influenza-specific CD4+Th1-cell responses. Influenza and Other Respiratory Viruses. 376-379.
  • Vis forfatter(e) (2011). Pandemic Influenza Vaccination Elicits Influenza-Specific CD4(+) Th1-cell Responses in Hypogammaglobulinaemic Patients: Four case reports. Scandinavian Journal of Immunology. 210-218.
  • Vis forfatter(e) (2011). Matrix-M adjuvanted virosomal H5N1 vaccine confers protection against lethal viral challenge in a murine model. Influenza and Other Respiratory Viruses. 426-437.
  • Vis forfatter(e) (2011). Intranasal c-di-GMP-adjuvanted plant-derived H5 influenza vaccine induces multifunctional Th1 CD4(+) cells and strong mucosal and systemic antibody responses in mice. Vaccine. 4973-4982.
  • Vis forfatter(e) (2011). Evaluation of the sublingual route for administration of influenza H5N1 virosomes in combination with the bacterial second messenger c-di-GMP. PLOS ONE. 12 sider.
  • Vis forfatter(e) (2011). Evaluation of a virosomal H5N1 vaccine formulated with Matrix M (TM) adjuvant in a phase I clinical trial. Vaccine. 8049-8059.
  • Vis forfatter(e) (2010). An adjuvanted pandemic influenza H1N1 vaccine provides early and long term protection in health care workers. Vaccine. 266-273.
  • Vis forfatter(e) (2009). Intramuscular Matrix-M-adjuvanted virosomal H5N1 vaccine induces high frequencies of multifunctional Th1 CD4+ cells and strong antibody responses in mice. Vaccine. 7367-7376.
  • Vis forfatter(e) (2009). A pilot study of the immune response to whole inactivated avian influenza H7N1 virus vaccine in mice. Influenza and Other Respiratory Viruses. 21-28.
  • Vis forfatter(e) (2009). A phase I clinical trial of a PER.C6 cell grown influenza H7 virus vaccine. Vaccine. 1889-1897.
  • Vis forfatter(e) (2009). A cell-based H7N1 split influenza virion vaccine confers protection in mouse and ferret challenge models. Influenza and Other Respiratory Viruses. 107-117.
  • Vis forfatter(e) (2007). Quality and kinetics of the antibody response in mice after three different low-dose influenza virus vaccination strategies. Clinical and Laboratory Immunology. 978-983.
  • Vis forfatter(e) (2007). A comparison of the humoral and cellular immune responses at different immunological sites after split influenza virus vaccination of mice. Scandinavian Journal of Immunology. 14-21.
  • Vis forfatter(e) (2006). The humoral immune response and protective efficacy of vaccination with inactivated split and whole influenza virus vaccines in BALB/c mice. Vaccine. 6585-6587.
  • Vis forfatter(e) (2006). The humoral and cellular responses induced locally and systematically after parenteral influenza vaccination in man. Vaccine. 6577-6580.
  • Vis forfatter(e) (2006). Impact of influenza vaccine formulation with a detailed analysis of the cytokine response. Scandinavian Journal of Immunology. 467-475.
  • Vis forfatter(e) (2005). Whole influenza virus vaccine is more immunogenic than split influenza virus vaccine and induces primarily an IgG2a response in BALB/c mice. Scandinavian Journal of Immunology. 36-44.
  • Vis forfatter(e) (2005). Two doses of parenterally administered split influenza virus vaccine elicited high serum IgG concentrations which effectively limited viral shedding upon challenge in mice. Scandinavian Journal of Immunology. 342-352.
  • Vis forfatter(e) (2002). Parenteral vaccination against influenza does not induce a local antigen-specific immune response in the nasal mucosa. Journal of Infectious Diseases. 878-884.
  • Vis forfatter(e) (2002). Non-lethal viral challenge of influenza haemagglutinin and nucleoprotein DNA vaccinated mice results in reduced viral replication. Scandinavian Journal of Immunology. 14-23.
  • Vis forfatter(e) (2001). The effect of zanamivir treatment on the early immune response to influenza vaccination. Vaccine. 4743-4749.
  • Vis forfatter(e) (2001). Non-lethal viral challenge of influenza haemagglutinin and nucleoprotein DNA vaccinated mice results in reduced viral replication. Scandinavian Journal of Immunology. 14-23.
  • Vis forfatter(e) (2001). High prevalence of influenza specific antibody secreting cells in nasal mucosa. Scandinavian Journal of Immunology. 243-247.
Vitenskapelig foredrag
  • Vis forfatter(e) (2023). Post COVID-19 condition in children and adolescents after delta infection and omicron reinfection.
  • Vis forfatter(e) (2023). Local Immunity After Influenza Vaccination.
  • Vis forfatter(e) (2023). Indo-European Consortium for Next Generation Influenza Vaccine Innovation.
  • Vis forfatter(e) (2022). SARS CoV-2 vaccines, what have we learnt and what is the future .
  • Vis forfatter(e) (2022). Covid-19 vaccine evaluation.
  • Vis forfatter(e) (2021). Pre-existing immunity and correlates of protection for Influenza.
  • Vis forfatter(e) (2021). Influenza and SARS-CoV-2 vaccines and the young immune system: should we vaccinate children.
  • Vis forfatter(e) (2021). Covid-19 i Bergen.
  • Vis forfatter(e) (2020). Influensa.
  • Vis forfatter(e) (2020). Case study: Influenza; impact of pre-existing immunity on study end points .
  • Vis forfatter(e) (2020). COVID-19 in the community and health care system in Bergen, Norway.
  • Vis forfatter(e) (2020). COVID-19 in the community and health care system in Bergen .
  • Vis forfatter(e) (2019). Immune responses to influenza A/H1N1pdm09 virus after adjuvanted pandemic and seasonal influenza vaccination in healthcare workers.
  • Vis forfatter(e) (2019). Critical Nodes of Viral Modulation Revealed Through an Integrated Network Analysis of Host-Virus Interaction Landscape.
  • Vis forfatter(e) (2018). Using human influenza vaccine studies to define next generation vaccines .
  • Vis forfatter(e) (2018). Subject selection and screening for susceptibility to challenge.
  • Vis forfatter(e) (2018). Should we vaccinate health care workers against influenza annually?
  • Vis forfatter(e) (2018). Should we annually vaccinate health care workers against influenza?
  • Vis forfatter(e) (2018). Hvorfor trenger vi fremdeles vaksiner? og Influensa en evig kamp. .
  • Vis forfatter(e) (2015). Cellular immune responses after live attenuated influenza vaccination in children, a clinical trial.
  • Vis forfatter(e) (2014). The Norwegian Influenza cohort study (NorFlu): immune responses in H1N1 pdm exposed versus non-exposed pregnant women.
  • Vis forfatter(e) (2014). The Norwegian Influenza cohort (NorFlu): immune responses in pdmH1N1 exposed versus non-exposed pregnant women.
  • Vis forfatter(e) (2014). Perinatal outcomes and children’s health after prenatal exposure to influenza infection and vaccination.
  • Vis forfatter(e) (2005). The humoral and cellular responses induced locally and systemically after parenteral influenza vaccination in man.
  • Vis forfatter(e) (2004). The antibody response to parenteral influenza vaccination � A review of specificity, magnitude, rapidity and shortcomings.
  • Vis forfatter(e) (2003). The local and systemic immune response to parenterally administered inactivated influenza vaccine.
  • Vis forfatter(e) (2003). The local and systemic immune response to parenterally administered inactivated influenza vaccine.
  • Vis forfatter(e) (2002). Influenzaantigenspecific cells in human nasal mucosa.
  • Vis forfatter(e) (2002). Influenza-specific antibody producing cells in human nasal mucosa.
  • Vis forfatter(e) (2002). Influenza-specific antibody producing cells in human nasal mucosa.
  • Vis forfatter(e) (2002). Influenza specific antibodysecreting cells in nasal mucosa, prior to and after vaccination.
  • Vis forfatter(e) (2002). Influenza specific antibody secreting cells in nasal mucosa.
  • Vis forfatter(e) (2001). The level of influenzaspecific antibodysecreting cells in nasal mucosa, prior to an after vaccination.
  • Vis forfatter(e) (2001). The effect of relenza treatment on the early immune response induced after influenza vaccination.
  • Vis forfatter(e) (2001). The basal level of influenza specific antibody secreting cells in healthy subjects.
  • Vis forfatter(e) (2001). Influenza specific antibody secreting cells (I-ASC)in human nasal mucosa. Relation to tonsil, blood and parenteral vaccination.
  • Vis forfatter(e) (2001). Influensaantigenspecifika, antikroppsproducerande lymfocyter i human nasal slemhinne.
  • Vis forfatter(e) (2001). DNA vaccination with HA or NP encoding plasmids results in rapid viral clearance after viral challenge.
  • Vis forfatter(e) (2001). Antibodies from lymphocytes used as diagnostic markers: A novel approach.
Populærvitenskapelig artikkel
  • Vis forfatter(e) (2020). COVID-19 og jakta på ein vaksine. Naturen.
  • Vis forfatter(e) (2018). Pandemivaksinen i 2009-en forberedelse til neste influensapandemi. Best practices.
Kronikk
  • Vis forfatter(e) (2020). Not just antibodies: B cells and T cells mediate immunity to COVID-19. Nature reviews. Immunology.
  • Vis forfatter(e) (2020). Det er ikke bare antistoffer som beskytter mot covid-19. Aftenposten (morgenutg. : trykt utg.).
  • Vis forfatter(e) (2020). CoVid-19; Derfor vil ikke dødeligheten være stor hvis viruset spres i Norge Norsk helsevesen er godt forberedt på at Wuhan-viruset kan spre seg til landet og beredskapen er på plass. Bergens Tidende.
  • Vis forfatter(e) (2018). Få en influensafri jul! Bergens Tidende.
  • Vis forfatter(e) (2017). Nok tro og folelser na. Bergens Tidende.
  • Vis forfatter(e) (2017). Gravide – se opp for fake news! Bergens Tidende.
  • Vis forfatter(e) (2015). Sølje Bergman er farligere for barn enn vaksiner. Bergens Tidende.
Vitenskapelig Kapittel/Artikkel/Konferanseartikkel
  • Vis forfatter(e) (2004). The kinetics of the systemic and local immune response to parenteral influenza vaccination. 4 sider.
  • Vis forfatter(e) (2003). Detection of antibodies to influenza virus in human mucosal tissues and fluids.
Sammendrag/abstract
  • Vis forfatter(e) (2011). Influenza Specific T-Cell Responses Predict Later Neutralizing Antibody Titres in a Phase 1 Clinical Trial of a Virosomal H5N1 Vaccine Adjuvanted with Matrix-M. Scandinavian Journal of Immunology. 355-355.
  • Vis forfatter(e) (2011). Comparison of Different Routes of Administration for Influenza Vaccines in a Murine Model. Scandinavian Journal of Immunology. 351-351.
Vitenskapelig oversiktsartikkel/review
  • Vis forfatter(e) (2023). Factors that impact on recruitment to vaccine trials in the context of a pandemic or epidemic: a qualitative evidence synthesis. Cochrane Database of Systematic Reviews. 74 sider.
  • Vis forfatter(e) (2022). COVID-19, Influenza and RSV: Surveillance-informed prevention and treatment – Meeting report from an isirv-WHO virtual conference. Antiviral Research.
  • Vis forfatter(e) (2021). A Research and Development (R&D) roadmap for influenza vaccines: Looking toward the future. Vaccine. 6573-6584.
  • Vis forfatter(e) (2020). Prospects and challenges in the development of universal influenza vaccines. Vaccines. 1-12.
  • Vis forfatter(e) (2018). Influensa-alltid relevant . Bestpractice Onkologi/Hematologi. 15-17.
  • Vis forfatter(e) (2018). Improving influenza vaccines: challenges to effective implementation. Current Opinion in Immunology. 88-95.
  • Vis forfatter(e) (2017). Immune responses after live attenuated influenza vaccination . Human Vaccines & Immunotherapeutics. 571-578.
  • Vis forfatter(e) (2013). The emergence of H7N9 viruses: A chance to redefine correlates of protection for influenza virus vaccines. Expert Review of Vaccines. 1369-1372.
  • Vis forfatter(e) (2009). Pandemic influenza vaccines - the challenges. Viruses. 1089-1109.
  • Vis forfatter(e) (2007). Influenza: the virus and prophylaxis with inactivated influenza vaccine in "at risk" groups, including COPD patients. The International Journal of Chronic Obstructive Pulmonary Disease. 229-240.
  • Vis forfatter(e) (2004). Influenza virus: Immunity and vaccination strategies. Comparison of the immune response to inactivated and live, attenuated influenza vaccines. Scandinavian Journal of Immunology. 1-15.
Fagartikkel
  • Vis forfatter(e) (2021). SARS-CoV-2; livssyklus, mutasjoner, immunreaksjoner og vaksiner. Bioingeniøren.
  • Vis forfatter(e) (2021). SARS-CoV-2; Mutasjoner og Varianter. . Bioingeniøren.
  • Vis forfatter(e) (2018). Immunrespons etter levende svekket influensavksine. Best practices.

Se fullstendig oversikt over publikasjoner i CRIStin.